PMID- 36672379
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230123
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 15
IP  - 2
DP  - 2023 Jan 9
TI  - Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma.
LID - 10.3390/cancers15020430 [doi]
LID - 430
AB  - (1) Background: High-dose chemotherapy (HDCT) followed by autologous stem cell 
      transplantation (ASCT) is the standard consolidation strategy for patients with 
      newly diagnosed multiple myeloma (MM) and for a subset of patients with 
      relapsed/refractory disease. For stem cell mobilization, G-CSF alone or in 
      combination with chemotherapy mobilizing agents and/or plerixafor are commonly 
      used. Ixazomib is an oral proteasome inhibitor with less neurotoxic potential, 
      which previously showed the ability to mobilize stem cells in preclinical 
      studies. (2) Methods: Prospective single-center phase 1 study assessing the 
      efficacy and safety of stem cell mobilization with ixazomib and G-CSF in patients 
      with newly diagnosed or relapsed/refractory MM undergoing HDCT and ASCT. Primary 
      endpoint was percentage of patients achieving a yield of at least 6.0 x 10(6)/kg 
      CD34+ cells within the first apheresis. G-CSF (filgrastim) 10 mug/kg/day was 
      administered subcutaneously (s.c.) from day 1 to day 5 (planned apheresis) and 
      ixazomib 4 mg orally at day 4. Plerixafor 24 mg s.c. was administered if the stem 
      cell mobilization with ixazomib and G-CSF was not sufficient. (3) Results: 19 
      patients were treated within the study between 06/2020 and 02/2021. The primary 
      endpoint was reached in 17 (89%) patients, with a median of 7.1 x 10(6)/kg CD34+ 
      cells collected within the first apheresis, comparable to previously published 
      results, and only 2 (11%) patients required a second apheresis. Median number of 
      circulating CD34+ cells was 14.0 x 10(6)/L (2.0-95.2) before the administration 
      of ixazomib, and 33.0 x 10(6)/L (4.2-177.0) pre-apheresis. However, 9 (47%) 
      patients required the addition of plerixafor to ensure optimal stem cell 
      collection. (4) Conclusions: The combination of ixazomib and G-CSF showed 
      promising stem cell mobilizing activity in patients with MM prior to HDCT and 
      ASCT. Future larger studies might further investigate the role of ixazomib in 
      stem cell mobilization regimens for MM.
FAU - Buhler, Selina
AU  - Buhler S
AD  - Department of Medical Oncology, Inselspital, Bern University Hospital, University 
      of Bern, 3010 Bern, Switzerland.
FAU - Akhoundova, Dilara
AU  - Akhoundova D
AUID- ORCID: 0000-0003-1639-3059
AD  - Department of Medical Oncology, Inselspital, Bern University Hospital, University 
      of Bern, 3010 Bern, Switzerland.
FAU - Jeker, Barbara
AU  - Jeker B
AD  - Department of Medical Oncology, Inselspital, Bern University Hospital, University 
      of Bern, 3010 Bern, Switzerland.
FAU - Legros, Myriam
AU  - Legros M
AD  - Department of Hematology and Central Hematology Laboratory, Inselspital, Bern 
      University Hospital, University of Bern, 3010 Bern, Switzerland.
FAU - Seipel, Katja
AU  - Seipel K
AUID- ORCID: 0000-0003-3128-1573
AD  - Department of Medical Oncology, Inselspital, Bern University Hospital, University 
      of Bern, 3010 Bern, Switzerland.
AD  - Department of Biomedical Research, University of Bern, 3008 Bern, Switzerland.
FAU - Daskalakis, Michael
AU  - Daskalakis M
AUID- ORCID: 0000-0002-8138-0505
AD  - Department of Hematology and Central Hematology Laboratory, Inselspital, Bern 
      University Hospital, University of Bern, 3010 Bern, Switzerland.
FAU - Bacher, Ulrike
AU  - Bacher U
AUID- ORCID: 0000-0001-8771-947X
AD  - Department of Hematology and Central Hematology Laboratory, Inselspital, Bern 
      University Hospital, University of Bern, 3010 Bern, Switzerland.
FAU - Pabst, Thomas
AU  - Pabst T
AUID- ORCID: 0000-0002-6055-5257
AD  - Department of Medical Oncology, Inselspital, Bern University Hospital, University 
      of Bern, 3010 Bern, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20230109
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9856560
OTO - NOTNLM
OT  - autologous stem cell transplantation (ASCT)
OT  - ixazomib
OT  - multiple myeloma
OT  - stem cell mobilization
COIS- The authors declare no conflict of interest.
EDAT- 2023/01/22 06:00
MHDA- 2023/01/22 06:01
PMCR- 2023/01/09
CRDT- 2023/01/21 01:12
PHST- 2022/12/07 00:00 [received]
PHST- 2022/12/27 00:00 [revised]
PHST- 2022/12/28 00:00 [accepted]
PHST- 2023/01/21 01:12 [entrez]
PHST- 2023/01/22 06:00 [pubmed]
PHST- 2023/01/22 06:01 [medline]
PHST- 2023/01/09 00:00 [pmc-release]
AID - cancers15020430 [pii]
AID - cancers-15-00430 [pii]
AID - 10.3390/cancers15020430 [doi]
PST - epublish
SO  - Cancers (Basel). 2023 Jan 9;15(2):430. doi: 10.3390/cancers15020430.